The experience of using the drug Pineamin to improve the quality of ejaculate and reduce the symptoms associated with male aging

Background. In recent years, there has been a continuous scientific search for new drugs to improve fertility and quality of life in men. One of these drugs is Pineamin — a complex of water-soluble polypeptide fractions of the bovine pineal gland, which is evaluated in this study. Objective. To evaluate the dynamics of ejaculate quality indicators and symptoms associated with male aging, against the background of the use of the drug Pineamin in comparison with a competitive intervention — the use of the drug L-carnitine. Material and methods. The pilot multicenter, randomized, parallel-group, interventional, comparative, prospective study included 60 men with pathozoospermia, divided into two comparable groups (Pineamin and L-carnitine). The study period was from May 2023 to December 2024. Spermogram parameters were determined and the AMS questionnaire was administered at baseline and after 3 months of the compared therapy. Results. In the group of patients treated with Pineamin, statistically significant differences were found in all the studied indicators of ejaculate quality before and after therapy. In the group of patients treated with L-carnitine, statistically significant differences were found only in sperm motility. When comparing the values of the changes in the studied parameters between the groups, statistically significant differences were revealed in all the studied indicators of ejaculate quality. The values of the changes in the studied parameters were more pronounced in the Pineamin group, were clinically significant and averaged 24 (95% CI 12; 36) million/ml for concentration, 18 (95% CI 12; 25)% for mobility and 2 (95% CI 1.5; 3.0)% for morphologically normal forms spermatozoa. Changes in the values of the studied parameters in the L-carnitine group were not clinically significant. The decrease in symptoms associated with male aging was statistically significant in the Pineamin group, while this was not observed in the L-carnitine group. Differences between the magnitude of changes in symptoms associated with male aging in the Pineamin and L-carnitine groups are statistically significant. The decrease in symptoms associated with male aging in the Pineamin group was –3 (95% CI –4; –1) points. No adverse events were observed. Conclusions. The use of the drug Pineamin may be promising in the treatment of men with pathozoospermia, as well as the relief of symptoms associated with aging.